Aduro Biotech Inc (KDNY)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

1600 FAIRVIEW AVE E. SEATTLE, WA 98102

Aduro Biotech, Inc provides immunotherapy services. The Company develops technology and vaccines for the treatment of early stage cancer and mesothelin-expressing tumors. Aduro Biotech serves customers in the United States.

Data as of 2020-11-22
Market Cap589.375 Million Shares Outstanding42.158 Million Avg 30-day Volume130.659 Thousand
P/E Ratio-15.2 Dividend Yield EPS-0.92
Price/Sales25.283 Price cash flow ratio Price free cash flow ratio-13.9
Book Value0.0 Price to Tangible Book89.41 Alpha-0.01
Short Interest Ratio % Short Interest to Float R-squared0.000384
BETA0.108247 52-week High/Low20.2 / 4.9 Stddev0.232739
View SEC Filings from KDNY instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 71 91 -21.98% 20 (1.31%) 30 (1.95%) -33.33%
13F shares: 7.533 Million 8.095 Million -6.94% 3.792 Million 4.416 Million -14.14%
% Ownership 23.2334 9.9861 132.66% 11.6944 5.448 114.65%
New Positions: 8 24 -66.67% 2 9 -77.78%
Increased Positions 13 28 -53.57% 3 9 -66.67%
Closed Positions 26 15 73.33% 12 5 140.0%
Reduced Positions 29 19 52.63% 10 6 66.67%
Total Calls 2.426 Thousand 54.53 Thousand -95.55% 2.38 Thousand 15 Thousand -84.13%
Total Puts 2.007 Thousand 10 19970.0% 2 Thousand
PUT/CALL Ratio 0.83 0.0 0.84 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding KDNY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KDNY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

6.5 Thousand total shares from 5 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DOBMEIER ERIC PRESIDENT, CEO

  • Officer
  • Director
52,837 2020-11-19 4

BJERKHOLT ERIC CHIEF FINANCIAL OFFICER

  • Officer
10,000 2020-11-16 1

GREENMAN WILLIAM MARINER

  • Director
0 2020-10-06 3

HAGHIGHAT ROSS

  • Director
0 2020-10-06 3

GRIFFIN MICHELLE RENEE

  • Director
0 2020-10-06 2

THOMAS DOLCA

  • Director
0 2020-10-06 2

JEREL DAVIS

  • Director
0 2020-10-05 2

FROHLICH TOM CHIEF BUSINESS OFFICER

  • Officer
0 2020-10-05 2

VERSANT VENTURE CAPITAL VII, L.P.

VERSANT VOYAGEURS I PARALLEL, L.P.

VERSANT VOYAGEURS I, L.P.

  • 10% Owner
7,888,369 2020-10-05 1

AKKARAJU SRINIVAS

  • Director
0 2020-10-05 2

KING ANDREW JAMES HEAD OF RENAL DISCOVERY

  • Officer
0 2020-10-05 2

GLICKLICH ALAN CHIEF MEDICAL OFFICER

  • Officer
0 2020-10-05 2

ISAACS STEPHEN T PRESIDENT AND CEO

  • Officer
  • Director
288,098 2020-09-15 4

TEMPLEMAN BLAINE CHIEF LEGAL OFFICER

  • Officer
121,916 2020-09-15 5

FERBER CELESTE SVP, GC AND SECRETARY

  • Officer
38,687 2020-09-15 5

NUYTEN DIMITRY SA CHIEF MEDICAL OFFICER

  • Officer
8,462 2020-08-07 3

KACHIOFF WILLIAM G INTERIM CFO

  • Officer
10,000 2020-06-01 2

OBRIEN STEPHANIE MONAGHAN

  • Director
0 2020-05-05 1

SHERWIN STEPHEN A

  • Director
0 2020-05-05 1

MACK DAVID HENRY

  • Director
0 2020-05-05 1

KARBE FRANK

  • Director
0 2020-05-05 1

VAN ELSAS ANDREA CHIEF SCIENTIFIC OFFICER

  • Officer
438,367 2020-02-25 5

WELCH JAMES H SEE REMARKS

  • Officer
0 2019-07-15 0

LEW JENNIFER CHIEF FINANCIAL OFFICER

  • Officer
135,155 2019-05-01 0

HOTH DANIEL FLOYD JR INTERIM CHIEF MEDICAL OFFICER

  • Officer
0 2018-11-29 0

SACKS NATALIE CHIEF MEDICAL OFFICER

  • Officer
173,720 2018-09-12 0

CHAN GERALD

  • Director
0 2018-06-06 0

MCCORMICK FRANK

  • Director
0 2018-06-06 0

SCHAFER GREGORY W CHIEF OPERATING OFFICER

  • Officer
254,062 2018-01-25 0

MORNINGSIDE VENTURE (VI) INVESTMENTS LTD

  • 10% Owner
9,305,532 2017-12-31 0

BROCKSTEDT DIRK G. EVP OF RESEARCH AND DEV.

  • Officer
124,603 2017-12-29 0

DUBENSKY THOMAS W. CHIEF SCIENTIFIC OFFICER

  • Officer
39,900 2017-08-10 0

ULTIMATE KEEN LTD

  • 10% Owner
5,602,499 2015-04-20 0

ROGERS JOHN E. AND LOIS A.

  • 10% Owner
148,245 2015-04-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-11-23 19:26:54 -0500 2020-11-23 P 929 $13.67 a 52,837 direct 1.5579 1.5579 2 0.0 1

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-11-23 19:26:54 -0500 2020-11-20 P 571 $13.69 a 51,908 direct 1.5579 1.5579 2 0.0 1

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-11-23 19:26:54 -0500 2020-11-19 P 500 $13.50 a 51,337 direct 1.5579 1.5579 2 0.0 1

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-11-13 18:13:14 -0500 2020-11-11 P 2,500 $13.75 a 50,837 direct -2.7816 -5.2156 0.0 1 -5.9805 3

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-11-13 18:13:14 -0500 2020-11-10 P 2,000 $13.86 a 48,337 direct -2.7816 -5.2156 0.0 1 -5.9805 3

GREENMAN WILLIAM MARINER - Director

2020-10-07 20:44:58 -0400 2020-10-06 A 23,522 a 23,522 direct

GLICKLICH ALAN - Officer CHIEF MEDICAL OFFICER

2020-10-07 21:15:12 -0400 2020-10-06 A 21,311 a 21,311 direct

THOMAS DOLCA - Director

2020-10-07 21:06:11 -0400 2020-10-06 A 23,522 a 23,522 direct

KING ANDREW JAMES - Officer HEAD OF RENAL DISCOVERY

2020-10-07 21:01:01 -0400 2020-10-06 A 30,455 a 30,455 direct

AKKARAJU SRINIVAS - Director

2020-10-07 21:08:04 -0400 2020-10-06 A 23,522 a 23,522 direct

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-10-07 20:57:21 -0400 2020-10-06 A 92,389 a 92,389 direct

GLICKLICH ALAN - Officer CHIEF MEDICAL OFFICER

2020-10-07 21:15:12 -0400 2020-10-06 A 62,660 a 62,660 direct

JEREL DAVIS - Director

2020-10-07 21:02:32 -0400 2020-10-06 A 23,522 a 23,522 direct

KING ANDREW JAMES - Officer HEAD OF RENAL DISCOVERY

2020-10-07 21:01:01 -0400 2020-10-06 A 89,545 a 89,545 direct

FROHLICH TOM - Officer CHIEF BUSINESS OFFICER

2020-10-07 20:59:07 -0400 2020-10-06 A 40,743 a 40,743 direct

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-10-07 20:57:21 -0400 2020-10-06 A 271,647 a 271,647 direct

FROHLICH TOM - Officer CHIEF BUSINESS OFFICER

2020-10-07 20:59:07 -0400 2020-10-06 A 119,793 a 119,793 direct

HAGHIGHAT ROSS - Director

2020-10-07 20:48:38 -0400 2020-10-06 A 23,522 a 23,522 direct

GRIFFIN MICHELLE RENEE - Director

2020-10-07 21:04:47 -0400 2020-10-06 A 23,522 a 23,522 direct

JEREL DAVIS - Director see footnote

2020-10-07 21:02:32 -0400 2020-10-05 A 722,247 a 722,247 indirect -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

KING ANDREW JAMES - Officer HEAD OF RENAL DISCOVERY

2020-10-07 21:01:01 -0400 2020-10-05 A 73,047 a 73,047 direct

FROHLICH TOM - Officer CHIEF BUSINESS OFFICER

2020-10-07 20:59:07 -0400 2020-10-05 A 98,847 a 98,847 direct

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-10-07 20:57:21 -0400 2020-10-05 A 463,358 a 463,358 direct

JEREL DAVIS - Director see footnote

2020-10-07 21:02:32 -0400 2020-10-05 A 4,733,023 a 4,733,023 indirect -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

FROHLICH TOM - Officer CHIEF BUSINESS OFFICER

2020-10-07 20:59:07 -0400 2020-10-05 A 153,398 a 153,398 direct -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

AKKARAJU SRINIVAS - Director see footnote

2020-10-07 21:08:04 -0400 2020-10-05 A 3,168,388 a 3,168,388 indirect -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-10-07 20:57:21 -0400 2020-10-05 A 46,337 a 46,337 direct -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

GLICKLICH ALAN - Officer CHIEF MEDICAL OFFICER

2020-10-07 21:15:12 -0400 2020-10-05 A 242,662 a 242,662 direct

JEREL DAVIS - Director see footnote

2020-10-07 21:02:32 -0400 2020-10-05 A 2,433,099 a 2,433,099 indirect -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

JEREL DAVIS - Director

2020-10-07 21:02:32 -0400 2020-10-05 A 730,470 a 730,470 direct -2.2156 -4.3114 -18.8623 5.3892 4 -28.7425 16

KING ANDREW JAMES - Officer HEAD OF RENAL DISCOVERY

2020-10-07 21:01:01 -0400 2020-10-05 A 73,047 a 73,047 direct

DOBMEIER ERIC - Director - Officer PRESIDENT, CEO

2020-10-07 20:57:21 -0400 2020-10-05 A 423,555 a 423,555 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments